Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1 - Sorbonne Université
Journal Articles Gene Therapy Year : 2022

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1

Abstract

Myotonic dystrophy, or dystrophia myotonica type 1 (DM1), is a multi-systemic disorder and is the most common adult form of muscular dystrophy. It affects not only muscles but also many organs, including the brain. Cerebral impairments include cognitive deficits, daytime sleepiness, and loss of visuospatial and memory functions. The expression of mutated transcripts with CUG repeats results in a gain of toxic mRNA function. The antisense oligonucleotide (ASO) strategy to treat DM1 brain deficits is limited by the fact that ASOs do not cross the blood-brain barrier after systemic administration, indicating that other methods of delivery should be considered. ASO technology has emerged as a powerful tool for developing potential new therapies for a wide variety of human diseases, and its potential has been proven in a recent clinical trial. Targeting DMPK mRNA in neural cells derived from human induced pluripotent stem cells obtained from a DM1 patient with the IONIS 486178 ASO abolished CUG-expanded foci, enabled nuclear redistribution of MBNL1/2, and corrected aberrant splicing. Intracerebroventricular injection of the IONIS 486178 ASO in DMSXL mice decreased the levels of mutant DMPK mRNAs by up to 70% throughout different brain regions. It also reversed behavioral abnormalities following neonatal administration. The present study indicated that the IONIS 486178 ASO targets mutant DMPK mRNAs in the brain and strongly supports the feasibility of a therapy for DM1 patients based on the intrathecal injection of an ASO.
Fichier principal
Vignette du fichier
s41434-022-00316-7.pdf (4 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03544255 , version 1 (26-01-2022)

Identifiers

Cite

Siham Ait Benichou, Dominic Jauvin, Thiéry de Serres-Bérard, Marion Pierre, Karen K Ling, et al.. Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1. Gene Therapy, 2022, ⟨10.1038/s41434-022-00316-7⟩. ⟨hal-03544255⟩
121 View
49 Download

Altmetric

Share

More